Low Nonrelapse Mortality after HLA-Matched Related 2-Step Hematopoietic Stem Cell Transplantation Using Cyclophosphamide for Graft-versus-Host Disease Prophylaxis and the Potential Impact of Non- Cyclophosphamide-Exposed T Cells on Outcomes.
Publication/Presentation Date
10-1-2020
Abstract
The use of cyclophosphamide (CY) for bidirectional tolerization of recipient and donor T cells is associated with reduced rates of graft-versus-host disease (GVHD) and nonrelapse mortality (NRM) after HLA-matched hematopoietic stem cell transplantation (HSCT). However, recurrent disease remains the primary barrier to long-term survival. We extended our 2-step approach to HLA-matched related HSCT using a radiation-based myeloablative conditioning regimen combined with a high dose of T cells in an attempt to reduce relapse rates while maintaining the beneficial effects of CY tolerization. After conditioning, patients received their grafts in 2 components: (1) a fixed dose of 2 × 10
Volume
26
Issue
10
First Page
1861
Last Page
1867
ISSN
1523-6536
Published In/Presented At
Montalban, X., Leist, T. P., Cohen, B. A., Moses, H., Campbell, J., Hicking, C., & Dangond, F. (2018). Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study. Neurology(R) neuroimmunology & neuroinflammation, 5(5), e477. https://doi.org/10.1212/NXI.0000000000000477
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
32629157
Department(s)
Administration and Leadership
Document Type
Article